| ²é¿´: 1583 | »Ø¸´: 7 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
[½»Á÷]
ÇóÖú¹ØÓÚÀûÒæ³åÍ»ÎÊÌ⣡¼±
|
|||
|
ÒòΪÎÄÕÂÖÐÁгöÁËÒ»¸ö¸øÎÒÃÇÌṩԲÄÁϵĹ«Ë¾µÄÈËQZ£¬ËùÒÔPLOS ONEдÁËEMAILÒªÇóÌṩÀûÒæ³åÍ»ÉùÃ÷£¬ÎÒÃÇÐ޻غóÓÖÀ´ÐÅ¡£ÏÖÔÚÏë°ÑQZÁÐÈëÖÂлÓÖÅÂÔÓ־ѯÎÊ×÷Õß±¾ÈËͬÒⱻɾ³ýÂð£¿ÁíÍ⣬ÔÚ²ÄÁÏÒ»ÏîÖУ¬ÎÒÃǶ¼Ð´³ÉÁË´Ó²úµØ¹«Ë¾¹ºÂòµÄ£¬Íü¼Çд³ÉQZÀ¡ÔùµÄÁË¡£Âé·³ÔÚ´ËÇóÖú¸÷룬ÈçºÎÈ¥»Ø´ð¡£ÏÈл¹ýÁË£¡ Dear Dr **, Thank you for submitting your manuscript entitled "**" to PLoS ONE. Your manuscript files have been checked in house but before we can proceed, we need you to address the following issues: 1) Thank you for submitting your revised paper, and for informing us of the following in your cover letter: "All authors declare that there are no conflicts of interest and approved to submit to your journal. We also declare that there are no conflicts of interests or financial disclosure, along with employment, consultancy, patents, products in development or marketed products with ** Pharmaceutical Industry Research Institute Co. Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials." We have reviewed this information and would like to suggest the following statements. Competing interest: "QZ is an employee of ** Pharmaceutical Industry Research Institute Co. Ltd. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials." Financial disclosure: "This work is supported by the National Natural Science Foundation of China (No: **). ** Pharmaceutical Industry Research Institute Co. Ltd., provided support in the form of a salary for author QZ, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ¡®author contributions¡¯ section.¡± Please respond by via the cover letter with your approval of the revised statements, if pertinent, alternatively please amend accordingly. We will change the online submission form on your behalf. [ Last edited by ph3719 on 2014-2-26 at 21:56 ] |
» ²ÂÄãϲ»¶
2026¹ú×ÔÈ»º¯ÆÀ·Ñµ½ÕË
ÒѾÓÐ22È˻ظ´
µ¼Ê¦Í²ۣºÎÒÔõô̯ÉÏÁËÕâô¸ö¼«Æ·Ñо¿Éú£¡
ÒѾÓÐ3È˻ظ´
2026ÄêµÄ¹ú¼ÒÉç¿Æ»ù½ðÏîĿͨѶÆÀÉóµÄйæÔòÓëж¯Ïò¡¢ÐÂÌôÕ½
ÒѾÓÐ7È˻ظ´
½ñÌì»ù½ð»á³ö½á¹ûÂð£¿20260819
ÒѾÓÐ18È˻ظ´
ÎÒÃæÉÏÍêµ°ÁË
ÒѾÓÐ14È˻ظ´
·¶½øÖоÙÒ»ÎĵÄÖÐÐÄ˼Ïë
ÒѾÓÐ8È˻ظ´
Ö»ÓÐÿÄêÕâÖÖʱºòÀ´¹ä¹äСľ³æ
ÒѾÓÐ27È˻ظ´
Ã÷ÌìÓ¦¸Ã¿É²éÁË£¡£¿
ÒѾÓÐ5È˻ظ´
Èç¹û´Ë¿ÌÄãÕýÔÚΪ¹ú»ù¸Ðµ½½¹ÂÇ£¬²»·ÁÀ´ÌýÌýÕâÊס¶»ù½ðÖ®Íâ¡·
ÒѾÓÐ7È˻ظ´
ûÓÐÈκÎÏûÏ¢-ÊDz»ÊǾÍÁ¹ÁË
ÒѾÓÐ8È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
µ°°×ŨËõºó³öÎÊÌâÁË£¬¼±ÇóÖú
ÒѾÓÐ7È˻ظ´
¼±£¡£¡£¡ÇóÖú £ºCHEMICAL ENGINEERING JOURNAL Ïà¹ØµÄͶ¸åÎÊÌâ
ÒѾÓÐ8È˻ظ´
¼±ÎÊһϣ¬ÊÕµ½±à¼²¿µÄÓʼþ£¬ÕâÊÇʲôÒâ˼£¿
ÒѾÓÐ11È˻ظ´
ÇóÖú¹ØÓÚ¼ÓÄôóǩ֤work permitµÄÎÊÌ⣡£¡£¡¼±£¡£¡~
ÒѾÓÐ5È˻ظ´
¼± nano letterͶ¸åϵͳ״̬ÎÊÌâÇóÖú
ÒѾÓÐ4È˻ظ´
ÇóÖú¹ØÓÚÖÐÎÄ¿ÆÑ§Í¨±¨Í¶¸åµÄÎÊÌ⣬¼±
ÒѾÓÐ19È˻ظ´
ÇóÖúÈçºÎÓò´ËÉ·½³Ì½â¼¸ºÎµç»¯Ñ§ÎÊÌ⣬¼±¼±¼±£¡£¡£¡
ÒѾÓÐ3È˻ظ´
WPSµÄÒ»¸öÎÊÌ⣡¼±£¡
ÒѾÓÐ10È˻ظ´
½ô¼±ÇóÖú£º¹ØÓÚ·É»úƱ·¢Æ±Ì§Í·µÄÎÊÌâ
ÒѾÓÐ9È˻ظ´
¼±~¹ØÓÚ²¨º¯Êý¶Ô³ÆÐÔµÄÎÊÌâÇóÖú
ÒѾÓÐ10È˻ظ´
Çó½ÌInternational journal of pharmaceutics Ͷ¸åµÄ¼¸¸öÎÊÌ⣡¼±~~~лл
ÒѾÓÐ5È˻ظ´
ÇóÖú£¬Í¶¸åÒªÇóÖеıí¸ñÎÊÌ⣬ͷ´ó£¬¼±£¬Ð»Ð»°ïÖú£¡
ÒѾÓÐ6È˻ظ´
¡¾ÇóÖú¡¿×Éѯһ¸ö¹ØÓÚDS-2019µÄÎÊÌ⣨¼±ÎÊ£©
ÒѾÓÐ10È˻ظ´
¡¾ÇóÖú¡¿£Å£Ä£Ã¡¢£Î£È£ÓÎÊÌâ,·Ç³£¼±£¬Ð»Ð»
ÒѾÓÐ8È˻ظ´
¡¾ÇóÖú¡¿¹ØÓÚÖÐҩѪÇåÒ©ÎﻯѧµÄһЩÎÊÌ⣬¼±£¡
ÒѾÓÐ17È˻ظ´
¡¾ÇóÖú¡¿¡¾ÇóÖú¡¿Êýѧ½¨Ä£ÎÊÌ⣬¡¶Ê³ÌþͲÍÎÊÌâ¡·¡£¡£¡£¼±£¡£¡£¡£¡£¡
ÒѾÓÐ11È˻ظ´
ÇóÖúѪ¹ÜÄÚÆ¤Ï¸°ûÅàÑøÎÊÌ⣨¼±£©
ÒѾÓÐ6È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
¸æ±ðÁ÷Ë®ÏßˬÎÄ£¡108Íò×ÖÍê½áÏÉÏÀ¡¶Å®æ´Ê¯Ö®ÁéÊ¯ÆæÔµ£¨ÏÉ½çÆª£©¡·ÖµµÃϸƷ
+1/5026
2026Ä깤³Ì¹ÜÀíÓëÖǻ۳ÇÊйú¼Ê»áÒé (EMSC 2026)
+1/670
Сľ³æÈÏʶµÄÀϹ«ÔÚÒ»Æð11Ä꣬ȥÊÀ¿ì100ÌìÁË¡£
+2/368
Õæ³ÏÕ÷ÓÑ
+1/186
»ù½ðÆí¸£
+1/154
É¢½ð±Ò
+1/121
ÉϺ£½»Í¨´óѧÕź½¿ÎÌâ×éÕÐÆ¸²©Ê¿ºó£¨µç»¯Ñ§ÄÜÁ¿´æ´¢Óëת»»£©
+1/98
ÉϺ£½»Í¨´óѧÕź½¿ÎÌâ×éÕÐÆ¸²©Ê¿ºó£¨µç»¯Ñ§´¢ÄÜ£©
+1/87
»ªÖпƼ¼´óѧÂÞ־ǿ½ÌÊÚ¿ÎÌâ×éÕÐÊÕ2027ÄêÇï¼¾Èëѧ²©Ê¿Ñо¿Éú
+2/86
Î人£¬³ÏÕ÷ÄÐÓÑ£¬²»ÒìµØ£¬ÄêÁä´óÁË
+1/37
Æí¸£»ù½ðµÃÖУ¬¿ÆÑÐÉúÑÄ˳ÀûÔ²Âú
+1/24
¡¾½»²æ¿ÆÑкÏ×÷¡¿³ÏÑû¶àѧ¿Æ½ÌÊÚ¡¢²©Ê¿¹²½¨Ñ§Éúʵ¼ù¿ÎÌâ¿â
+1/5
27É격-¼ÆËã»ú
+1/4
ÄϾ©´óѧ ÖÇÄÜÇý¶¯Óë¸ÐÖª²ÄÁÏʵÑéÊÒ ³ÏÕÐÉêÇ뿼ºË²©Ê¿Éú/¿ÆÑÐÖúÀí/²©Ê¿ºó
+1/4
Æíµ»ÀϹ«Öйú»ù
+1/3
¡¾¿ÆÑÐÏîÄ¿Õ÷¼¯¡¿Ò»Ïî¿ÉÔÚ 4¡ª8 ÖÜÍê³ÉµÄСÈÎÎñ£¬Ò²ÖµµÃ±»ÈÏÕæ¶Ô´ý
+1/2
³öȫвÌ˾ Plan?APOCHROMAT 20¡Á/0.8 ƽ³¡¸´ÏûÉ«²îÎï¾µ
+1/2
ÐÂÉó²éÖ¸ÄÏÊ©ÐаëÄ꣬AI·½ÏòµÄרÀûÉêÇëÊDz»ÊǸü¿´"¼¼Êõζ"ÁË£¿
+1/2
µ¥Ï¸°û²âÐòÑù±¾ÖƱ¸ÓëÖÊ¿ØÔËÊäÈ«Á÷³ÌÖ¸ÄÏ
+1/2
»ù½ð·Å°ñǰ
+1/1
8Â¥2014-02-27 09:20:50
¼òµ¥»Ø¸´
nowitzki_ci3Â¥
2014-02-26 23:38
»Ø¸´
ph3719(½ð±Ò+1): лл²ÎÓë
×£¸£ [ ·¢×ÔÊÖ»ú°æ http://muchong.com/3g ]
´÷¸Ö¿øµÄÖíÍ·5Â¥
2014-02-27 07:32
»Ø¸´
ph3719(½ð±Ò+1): лл²ÎÓë
¡£ [ ·¢×ÔÊÖ»ú°æ http://muchong.com/3g ]









»Ø¸´´ËÂ¥